US OptionsDetailed Quotes
OCGN241220P1000
- 0.12
- -0.03-20.00%
15min DelayClose Nov 29 13:00 ET
0.12High0.10Low
0.10Open0.15Pre Close5 Volume1.15K Open Interest1.00Strike Price58.00Turnover124.07%IV10.39%PremiumDec 20, 2024Expiry Date0.02Intrinsic Value100Multiplier21DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.4620Delta1.3613Gamma7.86Leverage Ratio-0.0027Theta-0.0003Rho-3.63Eff Leverage0.0009Vega
Ocugen Stock Discussion
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
No comment yet